Chinese API Manufacturer Draws FDA Warning Letter

By PacConAdmin | December 3, 2021

The FDA has closed out its three-year-old warning letter to Zhejiang Huahai Pharmaceutical’s site in Linhai, Taizhou because of corrective actions the manufacturer has undertaken.
Source: Drug GMP Report

Posted in Drug GMP Report